QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Oesophageal Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT07463573, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCC). Planned enrolment is 466 participants (estimated). The study started in 2026-04-20 and primary completion is expected in 2028-06-05. No results have been posted on ClinicalTrials.gov.